Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04513015

Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach

Inflammatory bowel disease (IBD), including Crohn's disease (CD), Ulcerative Colitis (UC) and IBD-unclassified (IBD-U) is a chronic inflammatory intestinal disorders that affect both children and adults. Patients with IBD can present with severe gastrointestinal symptoms, require frequent hospitalizations, expensive medical treatments and can develop invalidating complications requiring surgery. The incidence of IBD is increasing worldwide. The pathogenesis is multifactorial with immunological, environmental and genetic factors contributing to the disease. There is evidence that oxidative stress (OS) imbalance is involved in IBD onset and evolution, although the exact contribution to the pathogenes is unclear. An antioxidant dietetic approach is promising as an adjunctive treatment of IBD. The main aims of this project are to characterize the OS imbalance in IBD in relation to disease's features and to genetic factors and to evaluate the efficacy of an antioxidant dietetic treatment

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

6 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

SOD Clinica Pediatrica, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy

Loading trial locations.

About this study

IBD is a complex disorder that is thought to be the result of an aberrant immune response to commensal bacteria in a genetically susceptible host. The chronic inflammation along the gastrointestinal tract that characterizes IBD results from an imbalance of effector lymphocytes and pro-inflammatory cytokines. Some of the cytokines, as well as the triggered leukocytes and activated macrophages, can produce large amounts of reactive oxygen species (ROS) thus predisposing to oxidative stress disturbances. Many of the clinical and pathophysiological features of IBD, particularly tissue injury (mucosal erosions) and fibrosis have been associated to redox imbalance due to continuous ROS production and a net decrease of antioxidant molecules. Although uncontrolled oxidative stress is destructive in inflammatory conditions, the body's antioxidant defenses can counteract the effects caused by excess of ROS. Antioxidants are protective molecules/compounds toward pro-oxidant molecules. They can be endogenous or/and come from the diet. Endogenous compounds include intracellular enzymatic antioxidants such as superoxide dismutases (SODs), glutathione peroxidase (GPX), and catalase (CAT), intracellular nonenzymatic antioxidant such as glutathione (GSH) and extracellular antioxidants such as vitamins (Vit. A-C-E-B group). GSH is considered the major non-protein low molecular weight defender against oxidative (or redox) stress and the most important cellular thiol buffer. Moreover it acts as cofactor for the antioxidant enzymes GPxs and GST. GSH has been used as a biomarker for inflammation and several studies showed reduced levels of GSH in inflammatory conditions. Experimental colitis models showed decreased GSH levels that can be restored to a normal level by antioxidants supplementation. Also antioxidant enzymes as SODs, CAT and GPxs were found dysregulated in IBD condition. The differences in the regulation of expression of SOD, CAT and GPxs may not only reflect their importance in physiology, but may be also insufficient in removal of ROS under inflammatory conditions such as IBD.

Recently an association between SOD1, CAT and GSHPX1 polymorphisms and the risk of inflammatory bowel disease in the Polish population has been described. Kosaka et al. found a correlation between age of onset and severity of IBD with polymorphisms in SOD2 manganese superoxide dismutase and NAD(P)H quinone oxidoreductase. In this respect, IBD disease can be regarded as multifactorial disease. There are several lines of evidence to suggest that diet is a key player in the onset, perpetuation and management of IBD. The most important evidence linking diet to IBD comes from exclusive enteral nutrition (EEN) that is the primary induction treatment of active paediatric Crohn Disease (CD). Epidemiological evidence associates certain dietary nutrients and components to the increased risk of IBD. There is emerging evidence that some diets, including the Specific Carbohydrate Diet (SCD) and the CD Exclusion Diet (CDED) could treat or prevent subsequent disease flare. Data previously presented induce to the hypothesis that an antioxidant dietetic approach, could have a role in the treatment of IBD. Dietary antioxidants may include ascorbic acid, vitamin E, glutathione, methionine, carotenoids, polyphenolic compounds, selenium and vitamin A. Clinical experience evaluating antioxidant dietetic approach in IBD patients is limited to few studies, mostly investigating the effects of single antioxidants in small number of patients. So far pediatric data regarding the oxidative status in children with IBD have rarely been reported. Collecting data in IBD children and comparing these with adults data, particularly in subjects at diagnosis, would give the unique opportunity to evaluate the role of oxidative stress in IBD pathogenesis. OxIBDiet working hypothesis is that oxidative stress imbalance is a key feature of IBD and the persistence of such imbalance is likely to contribute to the development of complications and more broadly to the evolution of the disease. A comparison between oxidative stress imbalance in children and adults with IBD and controls will address the question whether the stress imbalance is a consequence or a primary event in the inflammatory burden of IBD. Addressing these pathways and targeting the oxidative damage can have potential implications in IBD monitoring and treatment.

This study has been granted by the Italian Ministry of Health (grant RF 2018-12366976)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of IBD

Exclusion criteria

  • permanent stoma
  • cancer
  • cardiovascular disease
  • ischemic disease
  • Alzheimer's disease
  • type 2 diabetes

Treatment and study plan

Antioxidant diet

Dietary Supplement

The "antioxidant diet" will include the principal antioxidant molecules/nutrients previously shown to be beneficial in IBD: Flavonoids, particularly resveratrol and curcumin; Olive oil; Glutathione, Vitamins A, C, E; Carotenoids; Selenium and Omega 3 Fatty Acids (PUFAs). The daily amount of these substances will be calculated following the published evidence, whether these amounts will not be achievable by a standard diet, a supplementary formulation will be proposed.

Normal dietetic scheme

Dietary Supplement

Isocaloric, normolipidic diet for age and sex

Primary outcomes

  1. Blood levels of ROS and glutathione in patients with IBD and controls

    Time frame: Baseline

    Blood levels of ROS will be determined by cytofluorimetry, blood levels of glutathione by spectrofluorimetry

  2. Total antioxidant capacity (Trolox equivalent and ferrous equivalent) in patients with IBD and controls

    Time frame: Baseline

    Trolox equivalent will be assessed by antioxidant assay Kit, ferrous equivalent instead wille require a manual assessment.

  3. Antioxidant enzymes pattern (GST, SOD, GPxs, GR enzyme levels, activity and transcripts) in patients with IBD and controls

    Time frame: Baseline

    Spectrophotometer will be used to assess enzyme levels and activity, cDNA kit to determine enzyme transcripts.

  4. Plasma hydroperoxides and thiobarbituric acid reactive species in patients with IBD and controls

    Time frame: Baseline

    Plasma hydroperoxides will be detected by LPO ELISA kit, thiobarbituric acid reactive species by TBARS assay kit.

  5. Urine oxidized guanines (8-OHdG, 8-OHG e guanosine) levels in patients with IBD and controls

    Time frame: Baseline

    DNA/RNA oxydate damage kit will be used to study urine oxidized guanines levels.

Secondary outcomes

  1. Polymorphisms of genes implicated in oxidative stress defense (SOD1, SOD2, SOD3; GPX1, GPX2, GPX3; GPX4; GPX5; GSTA1; GSTA2; GSTM1; GSTM2; GSTM3; GSTP1; GSTO1; NQ01 NQ02; NOX1; NOX3; NOX4 and NOX5 genes) in patients with IBD and controls

    Time frame: Baseline

    Genetic polymorphisms will be studied by next generation sequencing

Other outcomes

  1. Blood levels of ROS and glutathione in patients with IBD after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    Blood levels of ROS will be determined by cytofluorimetry, blood levels of glutathione by spectrofluorimetry at baseline and after 12 weeks of dietary treatment.

  2. Total antioxidant capacity (Trolox equivalent and ferrous equivalent) in patients with IBD after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    Trolox equivalent will be assessed by antioxidant assay Kit, ferrous equivalent instead wille require a manual assessment at baseline and after 12 weeks of dietary treatment.

  3. Antioxidant enzymes pattern (GST, SOD, GPxs, GR enzyme levels, activity and transcripts) in patients with IBD after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    Spectrophotometer will be used to assess enzyme levels and activity, cDNA kit to determine enzyme transcripts at baseline and after 12 weeks of dietary treatment

  4. Plasma hydroperoxides and thiobarbituric acid reactive species in patients with IBD after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    Plasma hydroperoxides will be detected by LPO ELISA kit, thiobarbituric acid reactive species by TBARS assay kit at baseline and after 12 weeks of dietary treatment.

  5. Urine oxidized guanines (8-OHdG, 8-OHG e guanosine) levels in patients with IBD after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    DNA/RNA oxydate damage kit will be used to study urine oxidized guanines levels at baseline and after 12 weeks of dietary treatment

  6. PUCAI in pediatric patients with RCU after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    PUCAI score will be recorded at baseline and after 12 weeks of dietary treatment

  7. PCDAI in pediatric patients with CD after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    PCDAI score will be recorded at baseline and after 12 weeks of dietary treatment

  8. Phisician Global Assessment (PGA) score in patients with IBD after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    PGA score will be recorded at baseline and after 12 weeks of dietary treatment

  9. Calprotectin levels in patients with IBD after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    Calprotectin levels will be analyzed in stool samples collected at baseline and after 12 weeks of dietary treatment

  10. Harvey-Bradshaw score in adult patients with CD after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    Harvey-Bradshaw score will be recorded at baseline and after 12 weeks of dietary treatment

  11. Mayo score in adult patients with RCU after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    Mayo score will be recorded at baseline and after 12 weeks of dietary treatment

  12. PedQoL score in pediatric patients with IBD after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    PedQoL score will be recorded at baseline and after 12 weeks of dietary treatment

  13. QoL score in adult patients with IBD after a specific antioxidant dietary treatment

    Time frame: 12 weeks

    QoL score will be recorded at baseline and after 12 weeks of dietary treatment

Sponsors and collaborators

Lead sponsor

Università Politecnica delle Marche

Other

Collaborators

  • Ministry of Health, Italy

Registry information

Official study title

Markers of Oxidative Stress in Inflammatory Bowel Disease in Children and Adults: Risk Factors and Implications for a Dietetic Approach

Acronym: OxIBDiet

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
Aug 14, 2020
Registry last updated
Dec 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.